GlassScriptPhysician profile
Stefanie J Bailey
NPI 1619328069
$3,638.08
in general payments reported to CMS, 2019-2025
22 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,225 · 2022: $575 · 2023: $723 · 2024: $505 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486.98 | 2021-2024 | |
| Almatica Pharma LLC | $474.52 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Otsuka America Pharmaceutical, INC. | $401.58 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $339.39 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $268.75 | 2021-2025 | |
| Axsome Therapeutics, INC. | $247.59 | 2024-2025 | Auvelity |
| Alkermes, INC. | $234.44 | 2023-2024 | Aristada, Aristada Initio |
| Lundbeck LLC | $202.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $148.71 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.33 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $112.28 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $110.53 | 2022-2025 | Fanapt |
| Bausch Health US, LLC | $83.50 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $72.97 | 2021 | |
| Merck Sharp & Dohme LLC | $72.72 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $53.58 | 2021 | |
| Sunovion Pharmaceuticals INC. | $52.53 | 2021 | |
| Avanir Pharmaceuticals, INC. | $40.03 | 2021-2022 | |
| Adlon Therapeutics L.P. | $29.58 | 2021 | |
| Corium, LLC | $29.44 | 2023 | Azstarys |
| Eisai INC. | $21.62 | 2021 | |
| Ironshore Pharmaceuticals INC. | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.